Efficacy of Oral Colchicine in Prevention of Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment
Information source: Shahid Beheshti Medical University
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Rhegmatogenous Retinal Detachment
Intervention: colchicine (Drug)
Phase: Phase 3
Status: Active, not recruiting
Sponsored by: Shahid Beheshti Medical University Official(s) and/or principal investigator(s):
Hamid Ahmadieh, MD, Principal Investigator, Affiliation: Ophthalmic Research Center of Shaheed Beheshti Medical University
Summary
This clinical trial will test the efficacy and safety of oral colchicine in prevention of
proliferative vitreoretinopathy (PVR) in cases of rhegmatogenous retinal detachment
Clinical Details
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Primary outcome: proliferative vitreoretinopathyretinal reattachment rate
Secondary outcome: visual acuityreoperation macular pucker
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Rhegmatogenous retinal detachment
Exclusion Criteria:
- PVR grade C
- Duration of retinal detachment ≥ one month
- History of cataract surgery
- History of RD surgery
Locations and Contacts
Hamid Ahmadieh,MD, Tehran 16666, Iran, Islamic Republic of
Additional Information
Starting date: March 2004
Last updated: October 6, 2006
|
